![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
3MB |
![[thumbnail of Supplementary Information incl. Source Data]](https://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Supplementary Information incl. Source Data)
16MB |
| Item Type: | Article |
|---|---|
| Title: | Towards a proteomic plasma biomarker panel for diagnosing vasculitis remission |
| Creators: |
Jerke, Uwe  ORCID: https://orcid.org/0000-0001-6887-8010, Kirchner, Marieluise ORCID: https://orcid.org/0000-0002-7049-534X, Bartolomaeus, Theda U.P. ORCID: https://orcid.org/0000-0002-5156-7184, Kling, Lovis ORCID: https://orcid.org/0000-0001-7894-6187, Kratky, Vojtech, Hruskova, Zdenka ORCID: https://orcid.org/0000-0002-2658-365X, Tesar, Vladimir ORCID: https://orcid.org/0000-0001-6982-0689, Eckardt, Kai-Uwe ORCID: https://orcid.org/0000-0003-3823-0920, Schreiber, Adrian ORCID: https://orcid.org/0000-0003-1244-6379, Forslund, Sofia ORCID: https://orcid.org/0000-0003-4285-6993, Mertins, Philipp ORCID: https://orcid.org/0000-0002-2245-528X and Kettritz, Ralph ORCID: https://orcid.org/0000-0001-5821-6718
|
| Abstract: | Active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) requires intensive immunosuppressive therapy, but continued treatment beyond remission risks serious harm. Because reliable biomarkers of remission are lacking, clinicians often prolong cost-intensive and toxic therapy unnecessarily. Here, we explore the plasma proteome to identify reliable biomarkers of disease remission in patients with AAV, adjusting for patient characteristics and clinical variables. Applying a two-tiered proteomics strategy that combines global discovery with targeted validation, we identify a protein signature of remission. We then implement the resulting 7-protein panel in a targeted mass spectrometry-based assay and confirm its diagnostic performance in an independent patient cohort. The panel consistently outperforms routine markers such as C-reactive protein and ANCA titer. Our findings suggest that this 7-protein panel provides a starting point for developing a clinical tool to support decision-making, with the potential to reduce treatment-related burden, mitigate toxicity, and lower healthcare costs. More broadly, our confounder-controlled proteomics approach provides a scalable blueprint for biomarker discovery in complex inflammatory diseases. |
| Keywords: | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Antineutrophil Cytoplasmic Antibodies, Biomarkers, C-Reactive Protein, Mass Spectrometry, Proteome, Proteomics, Remission Induction |
| Source: | Nature Communications |
| ISSN: | 2041-1723 |
| Publisher: | Nature Publishing Group |
| Volume: | 17 |
| Number: | 1 |
| Page Range: | 6825 |
| Date: | 21 July 2026 |
| Official Publication: | https://doi.org/10.1038/s41467-026-75755-6 |
| PubMed: | View item in PubMed |
| Related to: |
Repository Staff Only: item control page
